Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps.

Aims: Acute lung injury (ALI) is a life-threatening lung disease characterized by inflammatory cell infiltration and lung epithelial injury. Icariside II (ICS II), one of the main active ingredients of Herba Epimedii, exhibits anti-inflammatory and immunomodulatory effects. However, the effect and mechanism of ICS II in ALI remain unclear.

Preparation and evaluation in vitro of doxorubicin loaded mimetic exosomes-based delivery system.

Exosomes are focused as natural drug delivery vehicles with the advantages of biocompatible, biodegradable and non-immunogenic. However, the low yield of exosomes is one of the challenges that constrain its application. Mimetic exosomes (m-Exo) are the novel cell-derived nano-carriers with similar properties to exosomes and the substantially greater yield is attractive.

Preparation of 2-Methoxyestradiol Self-emulsified Drug Delivery System and the Effect on Combination Therapy with Doxorubicin Against MCF-7/ADM Cells.

Due to the poor solubility and bioavailability of 2-methoxyestradiol (2-ME), 2-ME emulsified drug delivery system (2-ME-SEDDS) was designed and characterized. After dilution with 5% glucose, 2-ME-SEDDS formed fine emulsions with mean diameter of 171 ± 14 nm and zeta potential of - 7.4 ± 0.